MA33373B1 - Composition pharmaceutique pour contraception d'urgence - Google Patents

Composition pharmaceutique pour contraception d'urgence

Info

Publication number
MA33373B1
MA33373B1 MA34470A MA34470A MA33373B1 MA 33373 B1 MA33373 B1 MA 33373B1 MA 34470 A MA34470 A MA 34470A MA 34470 A MA34470 A MA 34470A MA 33373 B1 MA33373 B1 MA 33373B1
Authority
MA
Morocco
Prior art keywords
contraceptives
urgent
pharmaceutical composition
pharmaceutical compositions
hand
Prior art date
Application number
MA34470A
Other languages
Arabic (ar)
English (en)
Inventor
Bernhard Lindenthal
Rolf Schürmann
Sascha General
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33373(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA33373B1 publication Critical patent/MA33373B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne, d'une part des compositions pharmaceutiques destinées à la contraception d'urgence, d'autre part l'utilisation de Lénovorgestrel associé à des inhibiteurs de cyclo-oxygénase pour la confection de compositions pharmaceutiques présentant l'effet mentionné, et enfin un procédé de confection de ces compositions pharmaceutiques.
MA34470A 2009-06-23 2010-06-10 Composition pharmaceutique pour contraception d'urgence MA33373B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009030607 2009-06-23
PCT/EP2010/003497 WO2010149273A1 (fr) 2009-06-23 2010-06-10 Composition pharmaceutique pour contraception d'urgence

Publications (1)

Publication Number Publication Date
MA33373B1 true MA33373B1 (fr) 2012-06-01

Family

ID=42830690

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34470A MA33373B1 (fr) 2009-06-23 2010-06-10 Composition pharmaceutique pour contraception d'urgence

Country Status (30)

Country Link
US (2) US8921345B2 (fr)
EP (2) EP3178476A1 (fr)
JP (2) JP5801801B2 (fr)
KR (1) KR20120044307A (fr)
CN (1) CN102458386B (fr)
AR (1) AR077199A1 (fr)
AU (1) AU2010265180B2 (fr)
BR (1) BRPI1011815A2 (fr)
CA (1) CA2766197C (fr)
CL (1) CL2011003291A1 (fr)
CO (1) CO6480948A2 (fr)
CR (1) CR20110699A (fr)
CU (1) CU20110239A7 (fr)
DO (1) DOP2011000402A (fr)
EA (1) EA023780B1 (fr)
EC (1) ECSP11011546A (fr)
ES (1) ES2625950T3 (fr)
HK (1) HK1170686A1 (fr)
IL (2) IL216668A (fr)
MA (1) MA33373B1 (fr)
MX (1) MX2011013959A (fr)
MY (1) MY158476A (fr)
NZ (1) NZ597239A (fr)
PE (1) PE20120860A1 (fr)
SG (1) SG177284A1 (fr)
TN (1) TN2011000656A1 (fr)
TW (1) TWI466673B (fr)
UA (1) UA108741C2 (fr)
UY (1) UY32728A (fr)
WO (1) WO2010149273A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890025A (zh) * 2009-05-20 2010-11-24 北京紫竹药业有限公司 孕二烯酮在制备紧急避孕药物中的应用
EP3178476A1 (fr) 2009-06-23 2017-06-14 Bayer Intellectual Property GmbH Composition pharmaceutique et procédé contraceptif d'urgence
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
FR2987271B1 (fr) * 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2730284A1 (fr) * 2012-11-12 2014-05-14 Naari AG Composition uniquement à base de levonorgestrel pour contraception orale optimisée avec contenu de lévonorgestrel défini, posologie et préparation pharmaceutique
EA201590903A1 (ru) * 2012-11-22 2015-11-30 Байер Фарма Акциенгезельшафт Применение и режим приема фармацевтической композиции, содержащей левоноргестрел и ингибитор цог, для контрацепции по мере необходимости ("on-demand")
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9655887B2 (en) 2013-05-23 2017-05-23 Bayer Pharma Aktiengesellschaft Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
KR101650778B1 (ko) 2014-10-17 2016-08-25 충북대학교 산학협력단 폴로유사인산화효소-1의 폴로박스 도메인에 특이적으로 결합하는 펩타이드 유사체 및 이를 유효성분으로 포함하는 피임용 조성물
WO2016203009A1 (fr) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Comprimé orodispersible contenant de l'estétrol
NO3106148T3 (fr) 2015-06-18 2018-08-11
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (fr) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN107383353A (zh) * 2017-08-31 2017-11-24 浙江道明光电科技有限公司 一种硅烷改性聚酯预聚物的制备方法
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
US11376263B2 (en) * 2020-10-08 2022-07-05 Fortress Biotech, Inc. Cyproterone acetate compositions and uses thereof
WO2022225986A1 (fr) * 2021-04-19 2022-10-27 Archer David Fitzgerald Contraceptif féminin à la demande
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031631A1 (fr) 1996-02-27 1997-09-04 Rpms Technology Limited Inhibiteurs selectifs de cox-2 destines a la maitrise de la periode de travail et des contractions uterines
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US20050143360A1 (en) * 2001-02-02 2005-06-30 Joel Krasnow Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
US20040058975A1 (en) * 2002-06-26 2004-03-25 Schering Ag Method for fertility control
EP3178476A1 (fr) 2009-06-23 2017-06-14 Bayer Intellectual Property GmbH Composition pharmaceutique et procédé contraceptif d'urgence
EA201590903A1 (ru) 2012-11-22 2015-11-30 Байер Фарма Акциенгезельшафт Применение и режим приема фармацевтической композиции, содержащей левоноргестрел и ингибитор цог, для контрацепции по мере необходимости ("on-demand")

Also Published As

Publication number Publication date
WO2010149273A1 (fr) 2010-12-29
IL244293A0 (en) 2016-04-21
EP3178476A1 (fr) 2017-06-14
UY32728A (es) 2011-01-31
AU2010265180A1 (en) 2012-01-19
MY158476A (en) 2016-10-14
IL216668A0 (en) 2012-02-29
CA2766197C (fr) 2017-07-25
SG177284A1 (en) 2012-02-28
BRPI1011815A2 (pt) 2016-03-29
NZ597239A (en) 2013-07-26
EP2445491B1 (fr) 2017-03-08
CU20110239A7 (es) 2012-04-15
AU2010265180B2 (en) 2014-09-11
TN2011000656A1 (en) 2013-05-24
EP2445491A1 (fr) 2012-05-02
EA023780B1 (ru) 2016-07-29
JP5801801B2 (ja) 2015-10-28
JP2015163646A (ja) 2015-09-10
TWI466673B (zh) 2015-01-01
TW201105330A (en) 2011-02-16
EA201200029A1 (ru) 2012-07-30
CR20110699A (es) 2012-03-12
PE20120860A1 (es) 2012-07-15
DOP2011000402A (es) 2012-01-15
US8921345B2 (en) 2014-12-30
US20120172343A1 (en) 2012-07-05
UA108741C2 (uk) 2015-06-10
CO6480948A2 (es) 2012-07-16
US9907806B2 (en) 2018-03-06
CL2011003291A1 (es) 2012-07-27
HK1170686A1 (zh) 2013-03-08
MX2011013959A (es) 2012-01-25
ECSP11011546A (es) 2012-01-31
JP2012530733A (ja) 2012-12-06
IL216668A (en) 2016-03-31
ES2625950T3 (es) 2017-07-21
CN102458386A (zh) 2012-05-16
US20150105359A1 (en) 2015-04-16
CA2766197A1 (fr) 2010-12-29
KR20120044307A (ko) 2012-05-07
CN102458386B (zh) 2016-04-06
AR077199A1 (es) 2011-08-10

Similar Documents

Publication Publication Date Title
MA33373B1 (fr) Composition pharmaceutique pour contraception d'urgence
EP1991218A4 (fr) Utilisation de cyclolignans dans le traitement du diabète de type 2 et comme contraceptifs
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
NZ594208A (en) Pharmaceutical compositions resistant to abuse
WO2008051942A3 (fr) Agonistes du récepteur farnésoïde x
IL194041A (en) A drug for the treatment of nocturnal offensive hemoglobinuria patients by a supplemental inhibitor
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
PL1981915T3 (pl) Kompozycje składników aktywnych
MX358617B (es) Formulaciones de inhibidores de dpp iv.
WO2010132882A8 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
FR2901467B1 (fr) Prothese anatomique pour le traitement des hernies, telles que hernies inguinales et crurales et autres
WO2007103200A3 (fr) Formulation orale à libération contrôlée pour des agents sédatifs ou hypnotiques
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
ATE524570T1 (de) Metallfolie
WO2005079751A3 (fr) Compositions pharmaceutiques orales de candesartan cilexetil
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2009006284A (es) Arilpirazoles sustituidos.
WO2011077239A3 (fr) Compositions pharmaceutiques d'ilopéridone à libération lente
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2008083130A3 (fr) Compositions à base de carvédilol
ZA201003794B (en) Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation
MX2010001243A (es) Composicion anti-inflamatoria.